Open AccessD-penicillamine Induced Myasthenia Gravis in Wilson’s Disease: A Case Report
Author(s) -
Lekhjung Thapa,
Monika Thapa,
Suman Bhattarai,
Abhishek Man Shrestha,
Nooma Sharma,
Nilshan Rai,
Merina Pokharel,
Raju Paudel
Publication year - 2022
Publication title -
journal of nepal medical association
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.176
H-Index - 19
eISSN - 1815-672X
pISSN - 0028-2715
DOI - 10.31729/jnma.7607
Subject(s) - medicine , myasthenia gravis , dysphagia , penicillamine , drooling , neuromuscular junction , etiology , disease , muscle weakness , pediatrics , weakness , surgery , neuroscience , biology
Myasthenia gravis is a neuromuscular junction disorder characterised by fluctuating muscle weakness, improved by using anti-cholinesterase drugs. In addition to the autoimmune aetiology, various factors such as infections, surgery, and drugs are known to precipitate the condition. We report a case of a 15-year-old boy with D-penicillamine-induced myasthenia gravis who presented with facial diplegia, dysphagia, and drooling of saliva, 6 years after the initiation of treatment for Wilson's disease. Therefore, clinicians should be more vigilant while prescribing patients with chelating drugs like D-penicillamine with regular monitoring of the new symptoms and keeping a very low threshold for the suspicion of myasthenia gravis.